EVT.F - Evotec AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Evotec AG

Manfred Eigen Campus
Essener Bogen 7
Hamburg 22419
Germany
49 40 5 60 81 0
http://www.evotec.com

Sector
Industry
Full Time Employees2,268

Key Executives

NameTitlePayExercisedYear Born
Dr. Werner LanthalerCEO & Member of Management Board792kN/A1968
Mr. Enno SpillnerCFO & Member of Management Board158kN/A1970
Dr. Mario PolywkaCOO & Member of Management Board614kN/A1963
Dr. Cord DohrmannChief Scientific Officer & Member of Management Board501kN/A1964
Ms. Anja BoslerPrincipal Accounting Officer and Sr. VP of Group AccountingN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services. The company is also involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. It has a strategic drug discovery and development partnership with Celgene Corporation to identify therapeutics in oncology; and a strategic alliance with Novo Nordisk A/S to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities; collaboration with Sanofi to develop LAB031, which accelerates drug discovery across various therapeutic areas; and a strategic research collaboration with Almirall, S.A. to discover and develop first-in-class therapeutics in the field of dermatology diseases, as well as strategic collaboration agreement with Centogene AG. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany.

Corporate Governance

Evotec AG’s ISS Governance QualityScore as of October 1, 2018 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.